![San Polo di Torrile, Italy. 12th October, 2018. Sunight is enlightening GSK logo on plant for innovative anti-HIV drug. GSK will produce Fostemsavir on behalf of ViiV Healthcare, the global specialist HIV San Polo di Torrile, Italy. 12th October, 2018. Sunight is enlightening GSK logo on plant for innovative anti-HIV drug. GSK will produce Fostemsavir on behalf of ViiV Healthcare, the global specialist HIV](https://c8.alamy.com/comp/PW64TM/san-polo-di-torrile-italy-12th-october-2018-sunight-is-enlightening-gsk-logo-on-plant-for-innovative-anti-hiv-drug-gsk-will-produce-fostemsavir-on-behalf-of-viiv-healthcare-the-global-specialist-hiv-company-majority-owned-by-glaxosmithkline-with-pfizer-inc-and-shionogi-limited-as-shareholders-gonewiththewindalamy-live-news-PW64TM.jpg)
San Polo di Torrile, Italy. 12th October, 2018. Sunight is enlightening GSK logo on plant for innovative anti-HIV drug. GSK will produce Fostemsavir on behalf of ViiV Healthcare, the global specialist HIV
![Gsk, 30 milioni di euro per un nuovo impianto a San Polo di Torrile: produrrà un farmaco sperimentale contro l'HIV Gsk, 30 milioni di euro per un nuovo impianto a San Polo di Torrile: produrrà un farmaco sperimentale contro l'HIV](https://www.parmatoday.it/~media/horizontal-hi/6197579984943/gsk-2.jpg)
Gsk, 30 milioni di euro per un nuovo impianto a San Polo di Torrile: produrrà un farmaco sperimentale contro l'HIV
![Gsk, 113 milioni di investimenti per il biotech di Parma (anche per la lotta contro il Covid)- Corriere.it Gsk, 113 milioni di investimenti per il biotech di Parma (anche per la lotta contro il Covid)- Corriere.it](https://www.corriere.it/methode_image/2020/12/07/Economia/Foto%20Economia%20-%20Trattate/Per%20web%20srgb%202048-12-kQwB-U3230193066013HbH-656x492@Corriere-Web-Sezioni.jpg)
Gsk, 113 milioni di investimenti per il biotech di Parma (anche per la lotta contro il Covid)- Corriere.it
![San Polo di Torrile, Italy. 12th October, 2018. Managers and workers of GSK and Italian authorities inaugurate the new plant to produce Fostemsavir, innovative drug for treatment-resistant HIV patients. GSK will produce San Polo di Torrile, Italy. 12th October, 2018. Managers and workers of GSK and Italian authorities inaugurate the new plant to produce Fostemsavir, innovative drug for treatment-resistant HIV patients. GSK will produce](https://c8.alamy.com/comp/PW5TY5/san-polo-di-torrile-italy-12th-october-2018-managers-and-workers-of-gsk-and-italian-authorities-inaugurate-the-new-plant-to-produce-fostemsavir-innovative-drug-for-treatment-resistant-hiv-patients-gsk-will-produce-fostemsavir-on-behalf-of-viiv-healthcare-the-global-specialist-hiv-company-majority-owned-by-glaxosmithkline-with-pfizer-inc-and-shionogi-limited-as-shareholders-gonewiththewindalamy-live-news-PW5TY5.jpg)
San Polo di Torrile, Italy. 12th October, 2018. Managers and workers of GSK and Italian authorities inaugurate the new plant to produce Fostemsavir, innovative drug for treatment-resistant HIV patients. GSK will produce
![San Polo di Torrile, Italy. 12th October, 2018. GSK and VIIV flags waving together in San Polo di Torrile plant. GSK will produce Fostemsavir on behalf of ViiV Healthcare, the global specialist San Polo di Torrile, Italy. 12th October, 2018. GSK and VIIV flags waving together in San Polo di Torrile plant. GSK will produce Fostemsavir on behalf of ViiV Healthcare, the global specialist](https://c8.alamy.com/comp/PW64G3/san-polo-di-torrile-italy-12th-october-2018-gsk-and-viiv-flags-waving-together-in-san-polo-di-torrile-plant-gsk-will-produce-fostemsavir-on-behalf-of-viiv-healthcare-the-global-specialist-hiv-company-majority-owned-by-glaxosmithkline-with-pfizer-inc-and-shionogi-limited-as-shareholders-gonewiththewindalamy-live-news-PW64G3.jpg)
San Polo di Torrile, Italy. 12th October, 2018. GSK and VIIV flags waving together in San Polo di Torrile plant. GSK will produce Fostemsavir on behalf of ViiV Healthcare, the global specialist
![San Polo di Torrile, Italy. 12th October, 2018. GSK and VIIV flags waving together in San Polo di Torrile plant. GSK will produce Fostemsavir on behalf of ViiV Healthcare, the global specialist San Polo di Torrile, Italy. 12th October, 2018. GSK and VIIV flags waving together in San Polo di Torrile plant. GSK will produce Fostemsavir on behalf of ViiV Healthcare, the global specialist](https://c8.alamy.com/comp/PW64GP/san-polo-di-torrile-italy-12th-october-2018-gsk-and-viiv-flags-waving-together-in-san-polo-di-torrile-plant-gsk-will-produce-fostemsavir-on-behalf-of-viiv-healthcare-the-global-specialist-hiv-company-majority-owned-by-glaxosmithkline-with-pfizer-inc-and-shionogi-limited-as-shareholders-gonewiththewindalamy-live-news-PW64GP.jpg)
San Polo di Torrile, Italy. 12th October, 2018. GSK and VIIV flags waving together in San Polo di Torrile plant. GSK will produce Fostemsavir on behalf of ViiV Healthcare, the global specialist
![San Polo Di Torrile, Italy - October 12, 2018: Sunight Is Enlightening GSK Logo On Plant For Fostemsavir, Innovative Anti-HIV Drug On The Day Of The Inauguration Stock Photo, Picture And Royalty San Polo Di Torrile, Italy - October 12, 2018: Sunight Is Enlightening GSK Logo On Plant For Fostemsavir, Innovative Anti-HIV Drug On The Day Of The Inauguration Stock Photo, Picture And Royalty](https://previews.123rf.com/images/gonewiththewind/gonewiththewind1810/gonewiththewind181000452/109721103-san-polo-di-torrile-italy-october-12-2018-sunight-is-enlightening-gsk-logo-on-plant-for-fostemsavir-.jpg)
San Polo Di Torrile, Italy - October 12, 2018: Sunight Is Enlightening GSK Logo On Plant For Fostemsavir, Innovative Anti-HIV Drug On The Day Of The Inauguration Stock Photo, Picture And Royalty
![San Polo di Torrile, Italy. 12th October, 2018. Managers and workers of GSK and Italian authorities inaugurate the new plant to produce Fostemsavir, innovative drug for treatment-resistant HIV patients. GSK will produce San Polo di Torrile, Italy. 12th October, 2018. Managers and workers of GSK and Italian authorities inaugurate the new plant to produce Fostemsavir, innovative drug for treatment-resistant HIV patients. GSK will produce](https://c8.alamy.com/comp/PW5TY8/san-polo-di-torrile-italy-12th-october-2018-managers-and-workers-of-gsk-and-italian-authorities-inaugurate-the-new-plant-to-produce-fostemsavir-innovative-drug-for-treatment-resistant-hiv-patients-gsk-will-produce-fostemsavir-on-behalf-of-viiv-healthcare-the-global-specialist-hiv-company-majority-owned-by-glaxosmithkline-with-pfizer-inc-and-shionogi-limited-as-shareholders-gonewiththewindalamy-live-news-PW5TY8.jpg)